Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Mayes

Showing results (321-330 of 382) with videos related to

Pageof 39
Sort By:
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Annals of the Rheumatic Diseases|July 17, 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severityKamini E Kuchinad, Ji Soo Kim, Adrianne Woods, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Journal of Scleroderma and Related Disorders|October 9, 2024
Changes in work and adequacy of financial resources during COVID-19 among people with systemic sclerosis: A Scleroderma Patient-centered Intervention Network studyClaire Adams, Elsa-Lynn Nassar, Marie-Eve Carrier, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
Pageof 39

Showing results (321-330 of 382) with videos related to

Sort By:
Pageof 39
NPJ Genomic Medicine|October 5, 2022
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosisMartin Kerick, Marialbert Acosta-Herrera, Carmen Pilar Simeón-Aznar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Distinct effects of complement C4A and C4B copy number in Systemic Sclerosis serological and clinical subtypesJavier Martínez-López, Carlos Rangel-Peláez, Inmaculada Rodriguez-Martin, et al.
Annals of the Rheumatic Diseases|July 17, 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severityKamini E Kuchinad, Ji Soo Kim, Adrianne Woods, et al.
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 22, 2020
Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung DiseaseShervin Assassi, Ning Li, Elizabeth R Volkmann, et al.
The Journal of Rheumatology|May 17, 2011
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysisRoozbeh Sharif, Marvin J Fritzler, Maureen D Mayes, et al.
Journal of Scleroderma and Related Disorders|October 9, 2024
Changes in work and adequacy of financial resources during COVID-19 among people with systemic sclerosis: A Scleroderma Patient-centered Intervention Network studyClaire Adams, Elsa-Lynn Nassar, Marie-Eve Carrier, et al.
Arthritis and Rheumatism|April 1, 2009
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trialDinesh Khanna, Philip J Clements, Daniel E Furst, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
ACR Open Rheumatology|March 30, 2022
47XXY and 47XXX in Scleroderma and MyositisR Hal Scofield, Valerie M Lewis, Joshua Cavitt, et al.
Pageof 39